Latest News
Agilent to Acquire Resolution Bioscience for USD 550m in Cash at Closing
Wednesday 03 March 2021

US-based life sciences company Agilent Technologies Inc. (NYSE: A) has agreed to acquire Washington-based oncology solutions provider Resolution Bioscience Inc. for USD 550m in cash at closing, the company said.

Under the terms of the agreement, Agilent will pay up to an additional USD 145m based on achieving future performance milestones.

The transaction is expected to close in April, subject to regulatory approvals and customary closing conditions.

The acquisition strengthens Agilent's position in NGS-based cancer diagnostics, providing the company with technology to further serve the needs of the precision medicine market.

Agilent Technologies Inc. operates in life-sciences, diagnostics, and applied-chemical markets, delivering insight and innovation toward improving the quality of life.

Resolution Bioscience Inc. develops and commercialises next-generation sequencing -based precision oncology solutions.
Date Published: 03/03/2021